Compare Travere Therapeutics Inc. Common Stock (TVTX) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs VF Corp — how do they compare? Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B), while VF Corp trades at $16.6 (market cap $6.48B). The key difference: VF Corp is the larger of the two by market cap, and VF Corp pays a 2.18% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and VF Corp for 64 Days on average.
| TVTX | VFC | |
|---|---|---|
Market Cap | $5.02B | $6.48B |
Volume | 2,060,842 | 18,946,837 |
Sector | Health | Consumer Cyclical |
52-Week High | $67.52 | $21.55 |
52-Week Low | $26.79 | $12.62 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $5.15B | $10.76B |
Dividend Yield | — | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
VFC trades at $16.07, up 1.77% today, with bullish technical signals from moving averages and ADX indicators. The company reported mixed quarterly results with a Q4 2025 earnings beat but subsequent misses, while revenue declined from $11.8B in 2022 to $9.5B in 2025. Analyst consensus shows a Hold rating with a $18.18 price target, representing 13% upside potential from current levels.
VFC's turnaround faces execution risks from Vans brand weakness despite strength in Outdoor segments. The stock trades at discounted valuations with P/S of 0.69, but negative net income and declining revenue trends require careful monitoring. Dividend sustainability remains a concern following the recent 82% cut, though institutional buying and technical momentum provide near-term support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
